Forterre Gael

SEC source: 0001477932-26-001491 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 331,338

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 12,700 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-26-001146 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 336,589

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 5,523 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-26-001105 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 338,872

F1 · shares: On February 26, 2026, the reporting person was awarded 149,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on March 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the vesting date.

SEC source: 0001477932-26-000607 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 189,872

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 4,863 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-26-000371 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 191,882

F1 · shares: On March 17, 2025, the reporting person was awarded 127,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to June 30, 2025 and December 31, 2025 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 38,100 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 12,700 units on each of March 17, 2026, 2027 and 2028, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. The rights with respect to the remaining 88,900 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026, respectively.

SEC source: 0001477932-25-007898 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 153,782

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 4,864 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-25-007403 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,535

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 15,333 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-25-007228 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,924

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 13,725 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-25-006094 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 166,427

F1 · shares: On August 15, 2025, the reporting person was awarded 9,727 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in six approximately equal monthly installments commencing on September 1, 2025. Once earned, they will remain subject to additional time-based vesting in two installments of 4,864 units and 4,863 units on each of November 1, 2025 and February 1, 2026, respectively, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the applicable vesting date.

SEC source: 0001477932-25-005470 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,700

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 6,690 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-25-004369 · form4.xml · nonDerivative · entry 2

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,462

F2 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 10,240 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-25-004369 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,696

F1 · shares: On June 1, 2025, the reporting person was awarded 6,690 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three equal installments of 2,230 units on each of June 1, 2025, July 1, 2025 and August 1, 2025, respectively, are also subject to further time-based vesting in a single installment on August 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-25-004915 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 159,466

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 4,828 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-25-003316 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 159,006

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 8,944 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-25-001457 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,704

F1 · shares: On March 1, 2025, the reporting person was awarded 5,523 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three equal installments of 1,841 units on each of March 1, 2025, April 1, 2025 and May 1, 2025, respectively, are also subject to further time-based vesting in a single installment on March 1, 2026, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-24-007807 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,181

F1 · shares: On December 1, 2024, the reporting person was awarded 4,828 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 1,610 units, 1,609 units, and 1,609 units on each of December 1, 2024, January 1, 2025 and February 1, 2025, respectively, are also subject to further time-based vesting in a single installment on July 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-24-006283 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,353

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 15,333 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-24-006102 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,786

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 13,725 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-24-005503 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,610

F1 · shares: On September 1, 2024, the reporting person was awarded 10,240 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 3,414 units, 3,413 units, and 3,413 units on each of September 1, 2024, October 1, 2024 and November 1, 2024, respectively, are also subject to further time-based vesting in a single installment on June 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-24-005029 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,370

F1 · shares: On Sept 28, 2023, the reporting person was awarded 61,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to Dec 31, 2023 and June 30, 2024 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 15,250 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three installments of 5,083 units, 5,083 units, and 5,084 units on each of Sept 28, 2024, 2025 and 2026, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. As reported in Jan 2024, the rights with respect to 25,925 RSUs subject to the award previously vested and remain subject to time-based vesting. The rights with respect to the remaining 19,825 RSUs did not vest and were cancelled on August 15, 2024.

SEC source: 0001477932-24-003487 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,120

F1 · shares: On June 1, 2024, the reporting person was awarded 8,944 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 2,982 units, 2,981 units, and 2,981 units on each of June 1, 2024, July 1, 2024 and August 1, 2024, respectively, are also subject to further time-based vesting in a single installment on May 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-24-000417 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 128,176

F1 · shares: On September 28, 2023, the reporting person was awarded 61,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2023 and June 30, 2024 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 25,925 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three installments of 8,642 units, 8,642 units, and 8,641units on each of September 28, 2024, September 28, 2025 and September 28, 2026, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-23-007440 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,251

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 15,334 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-23-005792 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,778

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 10,236 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-23-005111 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,375

F1 · shares: On October 4, 2022, the reporting person was awarded 46,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 20,700 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 6,900 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. As reported in October 2022 and January 2023 respectively, the rights with respect to 8,050 RSUs and 17,250 RSUs subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-23-000264 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commerical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,675

F1 · shares: On October 4, 2022, the reporting person was awarded 46,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 17,250 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 5,750 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in October 2022, the rights with respect to 8,050 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-007696 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,425

F1 · shares: On October 4, 2022, the reporting person was awarded 46,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 8,050 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three installments of 2,684 units, 2,683 units, and 2,683 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0001477932-22-005690 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commerical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,375

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 10,237 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-22-004657 · form4.xml · derivative · entry 4

Forterre Gael · CIK 0001841637 · Chief Commerical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,728

Underlying: Common Stock · 24,524 shares

Expires 2031-08-03

F3 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 37,728 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 24,524 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 12,262 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 13,204 shares subject to the award previously vested and remain subject to time-based vesting.

F3 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 37,728 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 24,524 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 12,262 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 13,204 shares subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-004657 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commerical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,973

F1 · shares: On August 3, 2021, the reporting person was awarded 20,473 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 13,308 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 6,655 units and 6,653 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 7,165 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

SEC source: 0001477932-22-002185 · form4.xml · derivative · entry 4

Forterre Gael · CIK 0001841637 · Chief Commerical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,204

Underlying: Common Stock · 13,204 shares

Expires 2031-08-03

F3 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 37,728 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 13,204 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 6,602 shares on each of August 3, 2022 and August 3, 2023, respectively.

F3 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 37,728 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 13,204 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 6,602 shares on each of August 3, 2022 and August 3, 2023, respectively.

SEC source: 0001477932-22-002185 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commerical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,665

F1 · shares: On August 3, 2021, the reporting person was awarded 20,473 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 7,165 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 3,582 units and 3,583 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.